Notice of Intent to Publish a Funding Opportunity Announcement for Somatic Cell Genome Editing Translational Coordination and Dissemination Center (U24, Clinical Trial Not Allowed)
ID: 338909Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/338909
Timeline
    Description

    The National Institutes of Health (NIH) is forecasting a funding opportunity for the establishment of a Somatic Cell Genome Editing Translational Coordination and Dissemination Center (TCDC) as part of its Somatic Cell Genome Editing (SCGE) program. This initiative aims to accelerate the development of genome editing therapeutic agents by facilitating Investigational New Drug (IND) application enabling studies, establishing regulatory approval pathways, and disseminating successful strategies for initiating first-in-human clinical trials. The total estimated funding for this opportunity is $2,000,000, with one award expected to be made, and the application due dates are anticipated in Summer 2022, following the publication of the Funding Opportunity Announcement in Spring 2022. Interested applicants can reach out to Dr. Marrah Lachowicz-Scroggins at 301-827-8229 or via email at SCGEprogram@od.nih.gov for further information.

    Point(s) of Contact
    Marrah Lachowicz-Scroggins, Ph.D.
    (301) 827-8229
    SCGEprogram@od.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers, designated as a UG1 Clinical Trial Not Allowed cooperative agreement. This initiative aims to support leadership and expertise in integrating translational science into clinical trials, particularly focusing on multi-center, late-phase treatment trials across various cancer types and patient demographics. The total estimated program funding is $2 million, with an award ceiling of $850,000 and an expected two awards to be made. The Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2024, with applications due in late February 2025, and awards expected to be announced by March 1, 2026. Interested applicants should prepare their proposals accordingly.
    Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD)" through a U01 cooperative agreement mechanism. This initiative aims to support the optimization of promising genome editing-based therapeutic leads for ADRD, focusing on preparing these candidates for Investigational New Drug (IND)-enabling studies. The funding is crucial for advancing research in various forms of ADRD, including Frontotemporal Dementia and Lewy Body Dementia, by refining therapeutic candidates to ensure their safety and efficacy. Interested applicants can apply for up to $1 million in funding, with a total budget commitment of up to $3 million per year for two awards, and must submit their applications by November 19, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    The NINDS Human Cell and Data Repository (U24 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NINDS Human Cell and Data Repository (U24 - Clinical Trial Not Allowed)" aimed at supporting the National Institute of Neurological Disorders and Stroke (NINDS) in maintaining and expanding its repository of human cell lines, specifically fibroblast and induced pluripotent stem cells (iPSCs). The initiative seeks to facilitate basic and translational research in neurological disorders by generating new cell lines, ensuring quality assessment standards, and distributing these resources to qualified researchers globally. With a total funding commitment of approximately $1.4 million for fiscal year 2025, eligible applicants include a wide range of organizations, such as educational institutions and non-profits, while proposals focused on non-human cell resources are excluded. Interested parties must submit their applications by October 17, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Population Genomic Screening in Primary Care Sequencing Center (U01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is soliciting applications for the "Population Genomic Screening in Primary Care Sequencing Center (U01 - Clinical Trial Optional)" grant, aimed at establishing a Sequencing Center to support a new population screening network. This initiative focuses on providing genomic sequencing services for 20,000 study participants, particularly targeting actionable conditions identified by the CDC, such as hereditary breast and ovarian cancer and Lynch syndrome, while ensuring inclusive recruitment from health disparity populations. The program emphasizes collaboration with community stakeholders and primary care providers to enhance genomic testing and follow-up care, ultimately aiming to integrate genomic medicine into primary care and address health disparities. Interested applicants should note that the total budget for the first year is $600,000, with escalating costs for subsequent years, and the application deadline is December 2, 2024. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-24-023.html.
    Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the Centers of Excellence in Genomic Science (CEGS) program, aimed at supporting innovative, interdisciplinary research in genomic science. This program seeks to establish academic centers that will develop transformative genomic approaches to address significant biomedical challenges, with a focus on integrating advanced technological and computational methods. Each award can provide up to $1.5 million per year for a maximum of five years, with potential renewal for an additional five years, and applications are due by June 23, 2025. Eligible applicants include a range of institutions such as higher education entities, nonprofits, and various government organizations, while foreign entities are not eligible. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Single Source: The NIGMS Human Genetic Cell Repository (U42 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a non-competitive funding opportunity for a cooperative agreement to support the Human Genetic Cell Repository (HGCR), with a focus on maintaining and distributing a diverse collection of human cell lines and DNA samples for biomedical research. The initiative aims to enhance the repository's capacity by acquiring new cell lines from diverse populations, ensuring ethical practices in sample collection, and promoting inclusivity in research efforts. This funding opportunity provides up to $1.75 million annually for a five-year project period, with applications due by June 10, 2026. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the funding announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-055.html.
    Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders" (U01), aimed at supporting Investigational New Drug (IND)-enabling studies and clinical trial planning for innovative gene-based therapeutics targeting ultra-rare diseases affecting fewer than 6,000 individuals. The program seeks to advance promising therapeutic candidates through robust proof-of-concept data and facilitate the submission of IND applications to the FDA, thereby addressing significant unmet medical needs within the ultra-rare disease community. Eligible applicants include higher education institutions, nonprofits, and governmental agencies, with a project period not exceeding two years and application deadlines ranging from October 2023 to February 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided NIH link.
    Notice of Intent to Publish a Funding Opportunity Announcement for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases through collaborative, multi-site, patient-centric research, with a focus on addressing unmet clinical trial readiness needs. The estimated total program funding for this opportunity is $1,000,000, with the FOA expected to be published in 2024 and applications due later that year. Interested applicants can reach out to Dr. Tiina K. Urv at 301-827-2746 or via email at urvtiin@mail.nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Diagnostic Centers of Excellence (X01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity announcement for the establishment of Diagnostic Centers of Excellence (DCoE) as part of the Undiagnosed Diseases Network (UDN). The initiative aims to enhance the diagnostic journey for patients with undiagnosed diseases by creating a self-sustained network that provides expert diagnostic services and fosters scientific discovery, with a focus on utilizing genomics data. Eligible applicants will be clinical sites in the U.S. that can demonstrate the necessary infrastructure and expertise to conduct clinical evaluations and DNA sequencing, with the opportunity to enroll a minimum of five participants annually. Interested parties can contact Dr. Argenia Doss at argenia.doss@nih.gov or by phone at 301-827-1373 for further details. The program announcement is expected to be published in spring 2023, with applications due in early summer 2023, and the maximum period of performance for awarded projects will be five years.
    Advancing Genomic Medicine Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R21 Clinical Trial Optional)" aimed at stimulating innovative research in the integration of genomic information into clinical care, particularly for populations experiencing health disparities. This initiative encourages proposals that address implementation science, barriers to genomic medicine, and the integration of genomic data with health and social determinants, with a focus on enhancing health equity among underrepresented groups. The grant provides funding up to $250,000, with applications open from November 1, 2023, until the close date of February 11, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.